Healzen Therapeutics Co. Ltd. has patented new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a mitogen-activated protein kinase ...

Astrazeneca AB has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a protein cereblon (CRBN) binding moiety covalently linked to an estrogen receptor α (ER-α)-targeting moiety ...

This finding may open new avenues for targeting other dynamic RNA-binding proteins. "The degradation pattern was unusual," explains Dr. Benhamou. "But rather than a flaw, it turned out to be a clue.